Final Word - BioPharm International


Final Word

Final Word: New Jersey: Biotech's Ideal Lab Location

July 1, 2005

As the fourth largest center for biotechnology and life sciences in the US, New Jersey is home to 15 of the world's 20 largest pharmaceutical companies. More than half of all new medicines approved in the US are developed by New Jersey companies. New Jersey is an ideal location because it offers close proximity to the financial markets in New York and Philadelphia, and a highly skilled workforce, strong funding, government support, and academic expertise.

Final Word: NIH-Biopharm Interactions and the New NIH Conflict-of-Interest Regulations

June 1, 2005

. . . These new stringent rules will strongly impact the pipeline of scientific talent the NIH has provided the biopharm industry.

Final Word: The National Academies' Guidelines for Human Embryonic Stem-Cell Research

May 1, 2005

On April 26 the National Academies of Sciences and the Institute of Medicine released guidelines for human embryonic stem (hES) cell research, the result of eight months of deliberations by a human research ethics committee I co-chaired with MIT's Richard O. Hynes. Composed of scientists, physicians, lawyers, ethicists, a social scientist, and a private citizen, the committee held a two-day public workshop and numerous meetings. We also reviewed international guidelines, policies, and procedures in this field.

Final Word: Insurance for Biotech Companies

April 1, 2005

Biotechnology and life sciences companies come in all shapes and sizes. Some are multinational companies with vast resources and others are small companies working with a few new compounds. Regardless of size or market position, these companies should all have one common question of those that handle their insurance: Will their current insurance program protect their assets and investments in the event of a significant loss? Understanding the nature of risks, acquiring suitable insurance, and comprehending policy issues when claims arise are essential to protecting assets and obtaining reimbursement when losses occur.

Final Word: The Public Side of Science: The Cloning Three Ring Circus

March 1, 2005

In this century, we are unlikely to face biomedical issues more complex and controversial than that of human cloning coupled with embryonic stem cell research. With the stakes so high — promises of cures and therapies for a host of devastating diseases and medical conditions set against impassioned disputes about when life begins — the cloning debate has evolved beyond the realm of scientific discourse and into the spotlight of public opinion. Unfortunately, this intense scrutiny, largely fueled by the media, has resulted in the misrepresentation of facts, and the twisting of scientific opinions as statements about cloning are often taken out of their appropriate context. In an attempt to counteract this damaging trend, The Science Advisory Board decided to poll its members about some of the most controversial aspects of the cloning debate.

Final Word: Disposable Systems Meet Today's Manufacturing Needs

February 1, 2005

Disposable products and systems have come a long way since they first entered the small-lab market in the 1970s. Today they are available for practically every aspect of biopharmaceutical manufacturing. Disposable systems are used for filtration, clarification, purification, and separation applications used in the production of vaccines, monoclonal antibodies, and other therapies. As the use of disposable systems grows, the concept of a completely disposable manufacturing process is becoming a reality.

Final Word: Suppliers Can Help Companies Achieve Speed to Market

January 1, 2005

In today's competitive and fast-paced environment, owner companies must get products to market quickly and efficiently. By redefining how they provide services and products, suppliers can enhance their value and help owner companies reap the greatest financial returns.

PMPs  If Not Now, When?

December 1, 2004

Biopharmaceutical companies are developing clever technologies for plant made pharmaceuticals (PMPs). When will the promise for the future turn into reality?

Monoclonal Antibodies for Cancer

November 1, 2004

Cancer treatment has grown into a multibillion-dollar business responsible for saving and improving the lives of countless patients each year. One of the approaches generating a flurry of interest is monoclonal antibodies.



Click here